In Vivo Pharmacodynamic Evaluation of ALT-Induced Asthma Model (CAT#: STEM-AE-0673-LGZ)

Introduction

Autoimmune diseases are conditions in which your immune system mistakenly attacks your body. The immune system normally defends against bacteria such as bacteria and viruses. When it senses these foreign invaders, it sends a combat force against them. Usually, the immune system can tell the difference between foreign cells and your own. In autoimmune diseases, the immune system mistakes a part of the body, such as a joint or skin, for a foreign body. It releases proteins called autoantibodies that attack healthy cells. Some autoimmune diseases target only one organ. Type 1 diabetes damages the pancreas. Other diseases, such as systemic lupus erythematosus (SLE), can also affect the whole body.

Add to Cart Please Inquire

Principle Applications Procedure Materials Notes Related Products

Principle

Asthma is a chronic airway inflammatory disease characterized by variable airflow obstruction, airway hyperreactivity (AHR) and airway inflammation. The main clinical symptoms of asthma are shortness of breath, wheezing, coughing and increased mucus production after exposure to allergens. Its pathogenesis is caused by a complex interaction between genetic, epigenetic and environmental factors. The different pathological changes are mediated by airway epithelial cells, eosinophils, and T lymphocyte subsets, among which Th2 cells are thought to predominate in hypereosinophilic asthma with elevated levels of cytokines IL-4, IL-5, and IL-13. The classic mouse asthma model is the airway inflammation model induced by ovalbumin (OVA). The mice were sensitized by multiple intrabitoneal injection of OVA and stimulated by atomizing inhalation of OVA to establish the acute asthma model. Serum IgE and eosinophilic granulocyte levels in alveolar lavage fluid increased, and pathological tissue section staining showed increased airway mucus and inflammatory leukocyte infiltration.
Experimental Animals: C57BL/6, Balb/c, B-hIL33/hST2 mice
Modeling reagent: ALT (Alternaria )
Modeling method: Sensitization—1-5 days; Challenge—19-26days

Applications

Autoimmune Disease

Procedure

1. Disease model construction.
2. Mice dosing.
3. Efficacy monitoring.
4. Biochemical detection of tissue samples.

Materials

• Sample Type: liquid or powder

Other recommended products

In Vivo Pharmacodynamic Evaluation of B-luc Hep 3B plus Cells Induced Liver Cancer Models (CAT#: STEM-AE-0655-LGZ)
In Vivo Pharmacodynamic Evaluation of B-hFGF21 Mice (Cytokine Humanized Mice) (CAT#: STEM-AE-0456-LGZ)
In Vivo Pharmacodynamic Evaluation of B-hCD3EDG/hTROP2 Mice (Immune Checkpoint Humanized Mice) (CAT#: STEM-AE-0297-LGZ)
In Vivo Pharmacodynamic Evaluation of B-hCD3E/hCD70 Mice (Humanized Mice) (CAT#: STEM-AE-0645-LGZ)
In Vivo Pharmacodynamic Evaluation of Spontaneous Tumor Model in Old Mice (CAT#: STEM-AE-0658-LGZ)
In Vivo Pharmacodynamic Evaluation of U-2 OS Cell Line Based Bone Cancer (CAT#: STEM-AE-0005-LGZ)
In Vivo Pharmacodynamic Evaluation of B-hVEGFR2 Mice (Cytokine Humanized Mice) (CAT#: STEM-AE-0504-LGZ)
In Vivo Pharmacodynamic Evaluation of LPS Induced Endotoxic Shock in Mice (CAT#: STEM-AE-0136-LGZ)